Drug intelligence / Profile preview

ABBV-324

Development stage: Phase 1
Lead developer: AbbVie
Administration: Intravenous

Overview

ABBV-324 is an investigational drug being developed by AbbVie for the treatment of hepatocellular carcinoma (HCC) and squamous-cell non-small cell lung cancer (LUSC). It is currently being evaluated in clinical trials where it is administered intravenously, either as monotherapy or compared to lenvatinib. The primary aim of ongoing studies is to assess adverse events and changes in disease activity in adult participants with HCC or LUSC. The specific mechanism of action and molecular target for ABBV-324 have not been disclosed publicly as of now[1][2].

Beyond the preview

Go deeper on ABBV-324.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-324.

Explore the full profile